SYNTHESIS AND ANTI-CANCER ACTIVITY OF 3-CHLORO-N-PHENYLBENZAMIDE
Article Sidebar
Main Article Content
Abstract
Targeted chemotherapy is one of the popular cancer treatments. Many studies had shown that enzyme IKKβ is one of the key elements which essential for activation of cell proliferation in the NF-κB signaling pathways. Therefore, this enzyme was utilized as target for activity inhibition. The 3-Chloro-N-phenylbenzamide, an aryl amide compound, was designed and synthesized as a small molecule aimed to act as IKKβ inhibitor and possess anti-proliferative activity. The compound was simulated and docking with IKKβ enzyme by computer-aided process to evaluate for its potential therapeutic properties. The structure of this compound was characterized by spectroscopic methods. The results from infrared spectrum showed a singlet peak of secondary amine at wavenumber 3,352 cm-1 and a carbonyl amide peak at wavenumber 1,659 cm-1. The 1H Nuclear Magnetic Resonance spectrum showed two distinct regions of 10 protons; the –NH peak at 10.37 ppm and another nine aromatic protons in the range of 7.10 – 8.03 ppm. The fragmentation pattern from mass spectrum showed the remarkable base peak at m/z 135.2 which is the typical of benzoyl fragment peak with the molecular ion peak also corresponding with the molecular weight of compound which equals to 231. An MTT assay indicated the ability of the synthesized compound that can inhibit the growth of cervical cancer cell line (SiHa) with an IC50 of 22.4 µM. The result emphasized the possibility of targeted cancer therapy of this compound.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Journal of TCI is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence, unless otherwise stated. Please read our Policies page for more information.
References
Abdelaziz AM, Yu M, Li P, Zhong L, Singab ANB, et al. 2015. Synthesis and Evaluation of 5-Chloro-2-Methoxy-N-(4-Sulphamoylphenyl) Benzamide Derivatives as Anti-cancer Agents. Med Chem, 5:253-260. doi:10.4172/2161- 0444.1000272
Camidge DR. 2014. Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore. Clin Adv Hematol Oncol, 12(11):763-6.
El-Hashash, M.A.EA.M., Salem, M.S. & Al-Mabrook, S.A.M. 2018. Synthesis and anticancer activity of novel quinazolinone and benzamide derivatives. Res Chem Intermed. 44: 2545. https://doi.org/10.1007/s11164-017-3245-4
Florian R. G, Lars E, Tim F. G, Jin M P, Zhi-Wei L, Laurence J. E, Martin F. K, and Michael Karin. 2007. IKKb Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell. 118, 285 - 296.
Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A. 2012. Inhibitory kappa B kinases as targets for pharmacological regulation. Br J Pharmacol. 165(4):802-819.
Jost PJ, Ruland J. Aberrant. 2007. NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 109(7):2700-7. PubMed PMID: 17119127.
Kanduri M, Tobin G, Åleskog A, Nilsson K, Rosenquist R. 2011. The novel NF-κB inhibitor IMD-0354 Induces apoptosis in chronic lymphocytic leukemia. Blood Cancer J. 1(3):e12.
Laurent F. Bonnac, Guang-Yao Gao, Liqiang Chen, Steven E. Patterson, Hiremagalur N. Jayaram and Krzysztof W. Pankiewicz. 2007. Efficient Synthesis of Benzamide Riboside, a Potential Anticancer Agent, Nucleosides, Nucleotides and Nucleic Acids. 26:10-12, 1249-1253, doi: 10.1080/15257770701528222
Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. 2010. Identification of Known Drugs that Act as Inhibitors of NF-KB Signaling and their Mechanism of Action. Biochem Pharmacol. 79(9):1272-1280.
National Cancer Institute. Targeted Cancer Therapies. www.cancer.gov/cancertopics/factsheet/Therapy/targeted on May 4, 2016.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S.2016. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 4(9):e609-16. doi: 10.1016/S2214-109X(16)30143-7.
Sawada I, Hashimoto K, Sawada K, Kinose Y, Nakamura K, Toda A, et al. 2016. The Novel IκB Kinase β Inhibitor,IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice. Int J Gynecol Cancer. 26(4):610-8.
Tanaka A, Muto S, Konno M, Itai A, Matsuda H. 2006. A New IκB Kinase β Inhibitor Prevents Human Breast Cancer Progression through Negative Regulation of Cell Cycle Transition. Cancer research. PubMed PMID: 16397257
World Cancer Report. 2014. World Health Organization. 2014. pp. Chapter 1.1. ISBN 9283204298 Cited; May 24, 2018.
Yanting Z, Rena G. L, Peiyan L, Eun Y C, Samusi A, Arif H, Xinghuan W, Xuefeng L and Han C. D. 2016. Targeting IκB kinase β/NF-κB signaling in human prostate cancer by a novel IκB kinase β inhibitor Cmpound A. Mol Cancer Ther. 15(7): 1504 -1514.